Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Incyte Higher on Plan to Develop Treatment for Myelofibrosis
By Fatma Khaled
Dec 30, 2020 2:42 PM EST
PRESS RELEASES
Incyte Announces Acceptance And Priority Review Of BLA For Retifanlimab As A Potential Treatment For Patients With Squamous Cell Carcinoma Of The Anal Canal (SCAC)
By Business Wire
Jan 21, 2021 4:30 PM EST
INVESTING
Incyte Higher on Plan to Develop Treatment for Myelofibrosis
By Fatma Khaled
Dec 30, 2020 2:42 PM EST
PRESS RELEASES
Incyte And Cellenkos Enter Into Global Development Collaboration Agreement For CK0804
By Business Wire
Dec 30, 2020 7:30 AM EST
INVESTING
12 Best Stocks in the Nasdaq This Past Week: Tesla Drives High
By Fatma Khaled
Dec 19, 2020 10:30 AM EST
PRESS RELEASES
Incyte Announces Results Of Phase 3 RUXCOVID Study Of Ruxolitinib (Jakafi®) As A Treatment For Patients With COVID-19 Associated Cytokine Storm
By Business Wire
Dec 14, 2020 1:15 AM EST
PRESS RELEASES
Incyte To Present At Upcoming Investor Conference
By Business Wire
Dec 9, 2020 8:00 AM EST
PRESS RELEASES
Incyte Announces First Data From REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes In Patients With Steroid-Refractory Or Steroid-Dependent Chronic Graft-Versus-Host Disease
By Business Wire
Dec 4, 2020 12:30 PM EST
PRESS RELEASES
Incyte To Present At Upcoming Investor Conference
By Business Wire
Nov 12, 2020 8:00 AM EST
PRESS RELEASES
Xencor, MorphoSys And Incyte Enter Into Global Development Collaboration For Tafasitamab In Combination With Plamotamab
By Business Wire
Nov 11, 2020 4:02 PM EST
PRESS RELEASES
Data From Incyte's Oncology Portfolio Accepted For Presentation At The Society For Immunotherapy Of Cancer 2020 Annual Meeting
By Business Wire
Nov 9, 2020 8:00 AM EST
PRESS RELEASES
More Than 40 Abstracts From Incyte's Oncology Portfolio Accepted For Presentation At The 62nd Annual ASH Virtual Meeting
By Business Wire
Nov 4, 2020 3:55 PM EST
PRESS RELEASES
ACR 2020: Lilly And Incyte Highlight Positive Data For Olumiant® In Rheumatoid Arthritis
By PR Newswire
Nov 2, 2020 2:00 PM EST
PRESS RELEASES
Incyte Ranked Second Among Science Magazine's 2020 Top Biopharma Employers
By Business Wire
Oct 30, 2020 9:00 AM EDT
PRESS RELEASES
Nimble Announces Strategic Research Collaboration With Incyte To Discover Novel Peptide-Based Therapeutics
By Business Wire
Oct 5, 2020 12:00 PM EDT
PRESS RELEASES
CHMP Recommends Approval Of Lilly's Baricitinib For The Treatment Of Adults With Moderate To Severe Atopic Dermatitis
By PR Newswire
Sep 18, 2020 7:44 AM EDT
PRESS RELEASES
Incyte And MorphoSys To Host Investor Event To Discuss The Unmet Need And Global Opportunities For Tafasitamab In Non-Hodgkin Lymphomas
By Business Wire
Sep 17, 2020 4:03 PM EDT
PRESS RELEASES
Incyte Announces Recipient Of The Inaugural Incyte Ingenuity Award To Recognize Innovative Solutions That Address Needs In The GVHD Community
By Business Wire
Sep 9, 2020 10:05 AM EDT
PRESS RELEASES
Incyte Announces Pivotal GEOMETRY Mono-1 Study Results Of Capmatinib (Tabrecta™) In Patients With METex14 Metastatic Non-Small Cell Lung Cancer Published In NEJM
By Business Wire
Sep 2, 2020 5:04 PM EDT
PRESS RELEASES
Incyte To Present At Upcoming Investor Conference
By Business Wire
Sep 1, 2020 8:00 AM EDT
PRESS RELEASES
National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) To Its Clinical Practice Guidelines In Oncology For B-cell Lymphomas
By Business Wire
Aug 18, 2020 4:02 PM EDT
PRESS RELEASES
FDA Approves Monjuvi® (tafasitamab-cxix) In Combination With Lenalidomide For The Treatment Of Adult Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
By Business Wire
Jul 31, 2020 7:51 PM EDT
PRESS RELEASES
Incyte Announces REACH3 Trial Of Ruxolitinib (Jakafi®) In Patients With Chronic Graft-Versus-Host Disease Met Primary And Both Key Secondary Endpoints
By Business Wire
Jul 23, 2020 7:15 AM EDT
PRESS RELEASES
Incyte Announces Approval Of Tabrecta™ (capmatinib) In Japan For The Treatment Of Patients With Advanced Non-Small Cell Lung Cancer With METex14
By Business Wire
Jun 29, 2020 7:05 AM EDT
PRESS RELEASES
Incyte Investor Conference Update
By Business Wire
Jun 17, 2020 8:00 AM EDT
